Zacks: SONNET BioTherapeutics, Inc (NASDAQ:SONN) Given Consensus Rating of “Strong Buy” by Brokerages
Shares of SONNET BioTherapeutics, Inc (NASDAQ:SONN) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $7.00 for the company, according to Zacks. Zacks has also given SONNET BioTherapeutics an industry rank of 51 out of 254 based on the ratings given to its competitors.
Separately, Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of SONNET BioTherapeutics in a research report on Thursday.
SONNET BioTherapeutics (NASDAQ:SONN) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.05) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. SONNET BioTherapeutics had a negative return on equity of 1,025.86% and a negative net margin of 82.24%. Sell-side analysts forecast that SONNET BioTherapeutics will post -2.96 earnings per share for the current year.
About SONNET BioTherapeutics
SONNET BioTherapeutics, Inc is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets.
See Also: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SONNET BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SONNET BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.